ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "meta-analysis"

  • Abstract Number: 1771 • ACR Convergence 2022

    The Effectiveness of a Treat-to-target Strategy in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis

    Yanjie Hao1, Shereen Oon2 and Mandana Nikpour3, 1The University of Melbourne, Melbourne, Australia, 2The University of Melbourne Department of Medicine at St. Vincent’s Hospital Melbourne, Melbourne, Australia, 3The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia

    Background/Purpose: The concept of treat-to-target (T2T), a strategy in which treatment is directed to reach and maintain a defined goal such as remission or low…
  • Abstract Number: 1966 • ACR Convergence 2022

    Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

    Eva van Geel1, Bafrin Abdulmajid1, Annelies Blanken2 and Michael Nurmohamed3, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Amsterdam University Medical Center, Kortenhoef, Netherlands

    Background/Purpose: Controlling inflammation with tumour necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients is hypothesized to reduce their cardiovascular risk. Arterial wall thickness (carotid…
  • Abstract Number: 1996 • ACR Convergence 2022

    Individual Patient Data Meta-analysis on Continued Use of Glucocorticoids After Their Use as Bridging Therapy in Patients with Rheumatoid Arthritis

    Lotte van Ouwerkerk1, Patrick Verschueren2, Pascal de Jong3, Paul Emery4, Josef Smolen5, Robert Landewé6, Willem Lems7, Maarten Boers8, Tom Huizinga1, CF Allaart1 and Sytske Anne Bergstra9, 1Leiden University Medical Center, Leiden, Netherlands, 2University Hospital Leuven, Leuven, Belgium, 3ErasmusMC, Hendrik Ido Ambacht, Netherlands, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Medical University of Vienna, Vienna, Austria, 6Amsterdam University Medical Center, Meerssen, Netherlands, 7Amsterdam University Medical Centers, Amsterdam, Netherlands, 8Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 9LUMC, Leiden, Netherlands

    Background/Purpose: Short-term (< 3 months) treatment with glucocorticoids (GC) ("bridging") is recommended in the EULAR 2019 rheumatoid arthritis (RA) recommendations when starting a csDMARD in…
  • Abstract Number: 2016 • ACR Convergence 2022

    Safety and Efficacy Associated with Long-Term Low Dose Glucocorticoids in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

    Andriko Palmowski1, Sabrina Mai Nielsen2, Zhivana Boyadzhieva3, Abelina Schneider3, Anne Pankow3, Linda Hartman4, Jose Pereira da Silva5, John Kirwan6, Siegfried Wassenberg7, Christian Dejaco8, Robin Christensen9, Maarten Boers10 and Frank Buttgereit11, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, 3Charité-Universitätsmedizin Berlin, Berlin, Germany, 4Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, 5University of Coimbra, Rheumatology, Columbia, Portugal, 6University of Bristol, Bristol, United Kingdom, 7Rheumazentrum Ratingen, Ratingen, Germany, 8Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 9Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, 10Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 11Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany

    Background/Purpose: There is ongoing controversy about the safety and efficacy of long-term low dose glucocorticoids (GCs) in rheumatoid arthritis (RA). Our aim was to study…
  • Abstract Number: 2123 • ACR Convergence 2022

    Hierarchical Ranking of Biologic Disease-Modifying Antirheumatic Drugs and Targeted Systemic Therapies for Psoriatic Arthritis: A Network Meta-analysis

    Jesus Diaz1, Guillermo Quiceno2 and Adela Castro3, 1Hamilton Medical Center, Chattanooga, TN, 2UT Southwestern Medical Center, Dallas, TX, 3Hamilton Physician Group-Specialty Care, Dalton, GA

    Background/Purpose: There are an increasing number of biological and targeted DMARDs in PsA. However, challenges around treatment selection remain, given the few head-to-head studies directly…
  • Abstract Number: 0141 • ACR Convergence 2022

    Is Rituximab Associated with Worse Outcomes in COVID-19 Patients? A Meta-analysis

    Yasmin Gerais1, Chenyu Sun1, Bethany King2, Scott Lowe3, Biniyam Mohammed1, Rachel Bentley3, Yaru Li4, Binyu Wei5 and Chuanhui Xu6, 1Ascension Saint Joseph hospital, Chicago, IL, 2MercyOne Des Moines Medical center, Des Moines, IA, 3College of Osteopathic Medicine, Kansas City University, Kansas, MO, 4Swedish Hospital, Chicago, IL, 5Harvard Medical School, Boston, MA, 6Tan Tock Seng Hospital, Singapore, Singapore

    Background/Purpose: Rituximab targets the CD20 antigen to deplete B cells and is indicated for a number of autoimmune diseases and other conditions. Accumulating data suggest…
  • Abstract Number: 2169 • ACR Convergence 2022

    Cardiac Rhythm and Conduction Abnormalities in Systemic Sclerosis-meta-analysis

    Drashti Antala1, Angkawipa Trongtorsak1, Qingqing Meng1, Akshaya Ramachandran1, Aanshi Patel2, Pabitra Adhikari1, Prasun Pudasainee1 and Krutarth Pandya3, 1Ascension Saint Francis hospital, Evanston, IL, 2B.J. Medical College, Ahmedabad, Ahmedabad, India, 3Trumbull Regional Medical Centre, Warren, OH

    Background/Purpose: Systemic sclerosis( SSc) can primarily cause repeated focal ischaemic insults in the myocardium and result in irreversible myocardial fibrosis. Myocardial involvement, when becomes clinically…
  • Abstract Number: 0328 • ACR Convergence 2022

    Predicting Progression from Undifferentiated to Definitive Connective Tissue Diseases: A Systematic Review and Meta-analysis

    Sarah Dyball1, Mia Rodziewicz1, Claudia Mendoza Pinto2, Ian N. Bruce3 and Ben Parker4, 1The University of Manchester, Manchester, United Kingdom, 2Systemic Autoimmune Diseases Research Unit, High-Specialty Medical Unit-CIBIOR, Mexican Social Security Institute, Puebla, Mexico, 3Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 4Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom

    Background/Purpose: Undifferentiated connective tissue disease (UCTD) encapsulates a broad range of conditions including incomplete forms of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), some…
  • Abstract Number: 0426 • ACR Convergence 2022

    The Relative Efficacy of Biologic and Targeted Synthetic DMARDs in Ankylosing Spondylitis: A Network Meta-Analysis

    Jesus Diaz1, Guillermo Quiceno2, Cathy Lee Ching3 and Adela Castro4, 1Hamilton Medical Center, Chattanooga, TN, 2UT Southwestern Medical Center, Dallas, TX, 3University of Mississippi Medical Center, Jackson, MS, 4Hamilton Physician Group-Specialty Care, Dalton, GA

    Background/Purpose: There is an unmet medical need for the treatment of patients with active ankylosing spondylitis (AS) who have an inadequate response to NSAIDs. Prior…
  • Abstract Number: 0484 • ACR Convergence 2022

    Epidemiology and Predictors of Relapse in Giant Cell Arteritis: A Systematic Review and Meta-analysis

    Lien Moreel1, Albrecht Betrains1, Geert Molenberghs2, Steven Vanderschueren1 and Daniel Blockmans1, 1University Hospitals Leuven, KU Leuven, Leuven, Belgium, 2KU Leuven, Leuven, Belgium

    Background/Purpose: The aim of this study was to estimate the timing of relapse, the prevalence of multiple relapses and the predictors of relapse in patients…
  • Abstract Number: 0739 • ACR Convergence 2022

    Effect of Tailored Self-Management Interventions on Health Outcomes in Individuals with Chronic Musculoskeletal Conditions

    Ellen Wang1, Isabel Rodrigues2 and Linda Li3, 1University of British Columbia, Arthritis Research Canada, Vancouver, BC, Canada, 2McMaster University, GERAS Centre for Aging Research, Hamilton, ON, Canada, 3University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Self-management, has been recognized as an essential component of successful chronic musculoskeletal (MSK) management; yet existing reviews of self-management interventions have found only modest…
  • Abstract Number: 0803 • ACR Convergence 2022

    Performance of Adenosine Deaminase Activity in Sinovial Fluid for the Early Diagnosis of Tuberculous Arthritis: A Meta Analysis

    Juan Carlos Cortés-Quiroz1, Javier Ena2, José Antonio Bernal3 and José Rosas4, 1Marina Baixa Hospital, Mutxamel, Spain, 2Department of Internal Medicine. Marina Baixa Hospital, Villajoyosa, Spain, 3Rheumatology Department. Marina Baixa Hospital, Alicante, Spain, 4Rheumatology Department, Hospital Marina Baixa, Villajoyosa, Spain

    Background/Purpose: Adenosine deaminase (ADA) activity has shown good performance in diagnosing pleural, peritoneal, and meningeal tuberculosis. This study aimed to evaluate the performance of measuring…
  • Abstract Number: 0914 • ACR Convergence 2022

    The Impact of Autoantibodies (RF and ACPA) on the Efficacy of Biological Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Meta-analysis of Randomized Controlled Trials

    Kaoru Takase-Minegishi1, Stephan Böhringer2, Jackie Nam3, Yuko Kaneko4, Frank Behrens5, Saedis Saevarsdottir6, Jacqueline Detert7, Marjatta Leirisalo-Repo8, Désirée van der Heijde9, Robert Landewé10, Sofia Ramiro11 and Diane van der Woude12, 1Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, 2Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Leiden, Netherlands, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, United Kingdom, 4Keio University School of Medicine, Tokyo, Japan, 5CIRI/Rheumatology and Fraunhofer Institute, Translational Medicine and Pharmacology ITMP, Goethe University, Frankfurt, Germany, 6Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden and Faculty of Medicine, University of Iceland, Stockholm, Sweden, 7Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, 8Department of Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 9Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 10Amsterdam University Medical Center, Meerssen, Netherlands, 11Leiden University Medical Center, Leiden, Netherlands, 12Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: The impact of autoantibodies on the efficacy of bDMARDs in patients with rheumatoid arthritis (RA) is not yet clear. Despite the fact that this…
  • Abstract Number: 1240 • ACR Convergence 2022

    A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy for the Diagnosis of Cardiac Sarcoidosis

    Omar Abialmouna1, Mohamad Kalot2, Mohamad Hamade3, Ronak Bahuva2, Ariba Hasmi2, Aamir Ahmed2, Zachary Brumberger2, Jordan Troy2, Ali Choaib4, Ronak Bharucha2, Ross Moyer2, Karin Provost2, Brian Page2 and Umesh Sharma2, 1University at Buffalo, North Tonawanda, NY, 2University at Buffalo, Buffalo, NY, 3University of Miami, Miami, FL, 4Lebanese American University, Beirut, Lebanon

    Background/Purpose: Autopsy reports for patients with sarcoidosis have suggested that up to 25% have cardiac involvement, mostly undiagnosed. Given the limited diagnostic accuracy of endomyocardial…
  • Abstract Number: 1578 • ACR Convergence 2022

    Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis

    Francis Lao1, Cal Robinson2, Megan Schlorff1, Joycelynn Ewusie3, KAREN BEATTIE1 and Michelle Batthish1, 1McMaster University, Hamilton, ON, Canada, 2The Hospital for Sick Children, Hamilton, ON, Canada, 3St Joseph's Healthcare Hamilton, Hamilton, ON, Canada

    Background/Purpose: Kawasaki Disease (KD) is a common childhood vasculitis. Coronary artery aneurysms (CAAs) develop in approximately 25% of untreated KD patients. However, there is limited…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences